Skip to contentX
Xenetic Biosciences, Inc.
X
XBIOXenetic Biosciences, Inc. Q2 2026 · 10-Q
Revenue$660.60K$660.60K+12.0% vs Q2 2025 Net Income-$929.70K-$929.70KN/M vs Q2 2025 EPS Diluted-$0.41-$0.41N/M vs Q2 2025 Operating Income-$971,690N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Xenetic Biosciences, Inc. · CIK 1534525 · Engraved from SEC EDGAR
derived
Margins · derivedOperating margin-147.1%−24.3 pt vs Q2 2025
Net margin-140.7%−24.0 pt vs Q2 2025
ended Jun 30, 2026 · filed Aug 6, 2026 · 37 d after period end